Hypoxia is an imbalance between oxygen supply and demand, which deprives cells or tissues of sufficient oxygen. It is wellestablished that hypoxia triggers adaptive responses, which contribute to short-and long-term pathologies such as inflammation, cardiovascular disease and cancer. Induced by both microenvironmental hypoxia and genetic mutations, the elevated expression of the hypoxia-inducible transcription factor-1 (HIF-1) and HIF-2 is a key feature of many human cancers and has been shown to promote cellular processes, which facilitate tumor progression. In this review, we discuss the emerging role of hypoxia and the HIFs in the pathogenesis of multiple myeloma (MM), an incurable hematological malignancy of BM PCs, which reside within the hypoxic BM microenvironment. The need for current and future therapeutic interventions to target HIF-1 and HIF-2 in myeloma will also be discussed.
Introduction
Multiple myeloma (MM) is a hematological malignancy of unknown etiology, which affects plasma cells (PCs) in the bone marrow (BM). The key clinical features of MM include the production of a monoclonal paraprotein, amyloidosis, renal insufficiency, anemia, increased BM angiogenesis, osteolytic bone lesions, severe bone pain, spontaneous fractures and hypercalcemia. 1 Despite recent therapeutic advances, MM remains incurable, has a high rate of relapse and drug resistance, and patients currently have a median overall survival of 44 months. 2 Hypoxia is a dysregulation of the homeostatic balance between oxygen delivery and oxygen consumption, which causes cells or tissues to become deprived of sufficient oxygen. Associated with a number of short-and long-term pathologies, hypoxia is a key feature of the tumor microenvironment and has been shown to drive tumor progression and treatment resistance. [3] [4] [5] [6] [7] A hypoxic tumor environment most commonly arises when rapidly proliferating cells outgrow the existing vasculature, or in response to transient limitations in blood perfusion. Importantly, these situations apply strong selective pressure to tumor cell subsets that are able to adapt quickly to reduced oxygen availability. Consequently, cancers that adapt to hypoxia are highly aggressive, resistant to treatment and associated with a poor prognosis.
Hypoxia and cancer
In solid tumors, the uncontrolled growth of malignant cells creates a chronic, diffusion-limited state of hypoxia in which the innermost cells become progressively distanced from the host vasculature. Consequently, although solid tumors contain a heterogeneous range of oxygen pressures ranging from approximately 5% O 2 in the well-vascularized areas to complete anoxia (no oxygen) in the necrotic areas, the average oxygen pressure generally lies in the hypoxic range at approximately 1% O 2 . [8] [9] [10] Acute or fluctuating hypoxia can also result as a consequence of transient limitations in blood perfusionFfor example, severe structural abnormalities in tumor microvessels and disturbances in microcirculation, which cause cyclical cessation and reestablishment of blood supply.
Over the years, several different approaches have been used to measure tumor oxygen levels, including electron paramagnetic resonance oximetry, nuclear magnetic resonance spectroscopy and PET (reviewed by Hockel and Vaupel 10 ). The current 'gold standard' approach involves taking direct polarographic measurements using microsensor techniques; 11 however, this is invasive and not suitable for all situations. In fact, all of the current approaches have their own benefits and limitations, and no single method is considered universally applicable. Instead, researchers must weigh up factors such as the invasiveness of the procedure, the degree of resolution required and cost to determine which is best suited to a particular experiment. As discussed in detail elsewhere, 12, 13 contemporary studies commonly measure tumor hypoxia using indirect, radiobiological or immunohistochemical approachesFradiobiological assessments measure the fraction of the clonogenic cells in tumors that are hypoxic, and immunohistochemical approaches (perhaps the most widely used) identify hypoxic adducts in tumor preparations using antibodies to the well-characterized hypoxia marker, pimonidazole, or surrogate markers of hypoxia such as the hypoxia-inducible transcription factors (HIFs) factors, which are induced by hypoxia.
It is well-established that hypoxia promotes tumor progression and metastasis by selecting for aggressive cell clones and upregulating the expression of genes associated with proliferation, angiogenesis, survival, extracellular matrix remodeling, cell migration and invasion, and cancer stem cell maintenance. 14, 15 In line with this, the expression of hypoxia-inducible gene products or low pO 2 in the primary tumor is associated with invasive growth, metastasis, resistance to treatment and poor overall survival. [16] [17] [18] Experimental tumor models have also
shown that tumors containing a high proportion of hypoxic cells metastasize more frequently than genetically equivalent control tumors containing low numbers of hypoxic cells. [19] [20] [21] [22] Adaptation to hypoxia: the HIFs
Owing to the fundamental importance of oxygen for metabolism and survival, cells have evolved intricate response mechanisms to sense and respond to hypoxia by activating a variety of celland tissue-specific transcription programs. Although these mechanisms are believed to be evolutionarily conserved in all mammalian cells, not all cells respond to hypoxia in the same manner, or to the same degree, owing to differing oxygen requirements and sensitivities to hypoxic stress. 23 Adaptive responses to hypoxia are regulated by several transcription factors, including HIF-1, HIF-2, ETS-1, cAMP response element binding protein, activator protein-1 and nuclear factor-kB. [24] [25] [26] [27] [28] [29] [30] [31] Of these, the most important regulators of cellular responses to hypoxia are the HIFs.
The HIFs are heterodimeric complexes composed of an inducible a-subunit (HIF-1a, HIF-2a or HIF-3a) and a constitutively-expressed b-subunit (aryl hydrocarbon nuclear translocator, or ARNT). Of the three HIF family members, HIF-1 and HIF-2 are the most well-characterized. HIF-1 and HIF-2 have been shown to be the master regulators of oxygen homeostasis and they have pivotal roles in both embryonic development and postnatal physiology. 25, [32] [33] [34] [35] As yet, the role of the more distantly related HIF-3 remains unclear, as at least one of the HIF-3a isoforms (known as IPAS-1) appears to suppress hypoxiainduced gene expression. 36 To date, over 70 hypoxia-responsive HIF-1 and/or HIF-2 target genes have been identified, which encode proteins involved in angiogenesis, erythropoiesis, glycolysis, iron transport, cell proliferation and survival, and vascular remodeling. [3] [4] [5] [6] As summarized in Figure 1 , the stability and transactivation of HIF-1 and HIF-2 is tightly controlled by post-translational regulation of the a-subunit. [37] [38] [39] [40] [41] Under aerobic (normoxic) conditions, HIF-a proteins are rapidly degraded by the ubiquitinproteasome pathway (t 1/2 o5 min) following prolyl hydroxylase (PHD)-dependent hydroxylation of residues P402 and P564 within the oxygen-dependent degradation domain. 42 Under normoxic conditions, HIF-a proteins also undergo asparaginyl hydroxylation by the factor inhibiting HIF (FIH) enzyme, which represses HIF transcriptional activity by blocking the recruitment of the CBP/ p300 coactivator. 43 The absolute requirement for oxygen for PHD and FIH activity serves as the primary cellular oxygen sensor in these processes, and when oxygen levels become deficient, their activity is inhibited. Under hypoxic conditions, HIF-a hydroxylation is abrogated and proteasomal degradation is inhibited, thereby allowing HIF a-subunits to dimerize with the constitutively expressed b-subunit, ARNT. 44 Following the recruitment of additional transcriptional coactivators, the active HIF complex binds to hypoxia-response elements (5 0 -RCGTG-3 0 ) in target genes and initiates transcription programs to mediate adaptive cellular responses to hypoxia. 6, [44] [45] [46] [47] [48] In addition to environmental hypoxia, a number of studies have also shown that HIF-1a and HIF-2a protein levels can be and tensin homolog; [49] [50] [51] gain-of-function mutations in Myc, Ras and Raf [52] [53] [54] ), signaling malfunctions (for example, hyperactivated PI3K/Akt and Src 55, 56 ), growth factors and hormones, [57] [58] [59] [60] [61] and reactive oxygen species. 62, 63 To date, aberrant expression of HIF-1a and/or HIF-2a has been documented in cancers of the brain, colon, lung, breast, prostate, kidney, pancreas, cervix, bladder and ovary, [64] [65] [66] [67] [68] [69] and overexpression of both HIFs has been found to indicate a highly aggressive disease phenotype associated with poor prognosis. [70] [71] [72] [73] [74] [75] [76] Whereas examination of aberrant HIF expression has largely been restricted to solid tumors, recent studies have reported that HIF-1a and HIF-2a are also overexpressed in hematological malignancies such as diffuse large B-cell lymphoma, 77, 78 chronic lymphocytic leukemia 79 and acute lymphoblastic leukemia. 80 Although HIF-1a and HIF-2a show 48% amino-acid sequence homology and have similar protein structures and oxygendependent mechanisms of regulation, there are a growing number of physiological and mechanistic differences between these proteins, which indicates that they possess distinct, nonredundant roles. [81] [82] [83] [84] Of note, whereas both HIF-1 and HIF-2 bind to the same hypoxia-response element DNA consensus sequence in target gene promoters, 85, 86 they regulate both common and unique target genes. 25, 87, 88 While not entirely understood, this may, in part, be explained by the restricted expression of HIF-2a compared with the ubiquitous expression of HIF-1a; 65, 86, [89] [90] [91] [92] differing affinities for PHD-and FIHdependent regulation of HIF-a protein stability and transcriptional activity; and differential recruitment of isoform-specific transcriptional coactivators and/or repressors to the HIF-1 and HIF-2 complexes. [93] [94] [95] Several oxygen-dependent and oxygen-independent mechanisms of HIF-a protein degradation can dictate the selective recruitment of either HIF-1a or HIF-2a to ARNT to mediate celland tissue-specific adaptation to hypoxia. As discussed, HIF-a proteins are hydroxylated under normoxic conditions by the PHD enzymes, of which there are four known isoforms (termed PHD1, PHD2, PHD3 and PHD4). Each PHD isoform shows varying affinities for HIF-a hydroxylation, with PHD2 showing the highest affinity for HIF-1a hydroxylation 96 and PHD3 showing the highest affinity for HIF-2a hydroxylation. 97 In addition, regulators of HIF1a and HIF-2a protein stability such as human hypoxia-associated factor (HAF) and murine integration site-6 confer isoform-specific degradation of these proteins independently of oxygen tensions. HAF (also known as SART1 800 ) 98 is a novel E3 ligase, which specifically binds to and ubiquitinates HIF-1a (but not HIF-2a) to direct its proteasomal degradation under normoxic conditions. 99 Whereas having no clear homology with other ubiquitin ligases, integration site-6 has been described as an HIF-2a-specific E3 ligase, which degrades HIF-2a through an unidentified ubiquitin ligase and the 26S proteasome. 100 As recently reviewed by Majmundar et al., 101 the regulation of the HIF pathway is further complicated by the identification of a growing list of environmental cues, such as microRNAs, redox homeostasis and cellular metabolites, which are known to modulate the HIF pathway.
It is becoming increasingly apparent that HIF-1 and HIF-2 contribute to tumorigenesis in a complex, context-dependent manner. For example, whereas HIF-1a expression positively correlates with decreased patient mortality in many cancers, HIF-2a expression is a negative prognostic factor in many of these same cancers (reviewed by Bertout et al. 102 ). In VHLdeficient renal cell carcinoma, overexpression and knockdown studies have shown that HIF-2a promotes tumor growth whereas HIF-1a inhibits tumor growth, 103 and in some cancers, HIF-1 binds to and stabilizes p53 to mediate hypoxia-induced apoptosis, whereas HIF-2 suppresses p53 and promotes chemoresistance. 104, 105 Therefore, tumor behavior and drug response can vary significantly according to aberrant expression of HIF-1a and/or HIF-2a in different cancers.
The BM microenvironment
While the BM microenvironment has long been considered to be physiologically hypoxic, 106 ,107 a lack of direct non-invasive techniques has hindered accurate in situ measurement of BM oxygen levels. Using polarographic oxygen electrodes to measure intra-medullary oxygen tensions in the femoral head of surgical patients during fracture fixation, Watanabe et al. 109 reported intra-medullary oxygen levels of 23-27 mm Hg. In recent studies, immediate assessment of oxygen levels in human BM aspirates showed an average oxygen tension of 54 mm Hg, 110 which, while still considered hypoxic, is markedly higher than reported by others.
Using a surrogate marker of hypoxic adducts, pimonidazole, recent murine studies have shown that the BM in fact contains a heterogeneous O 2 distribution and that distinct BM compartments contain different oxygen tensions. [111] [112] [113] The 'endosteal niche' located at the bone-BM interface is strongly hypoxic, marked by high levels of HIF-1a expression and pO 2 tensions below 10 mm Hg. By contrast, the central 'vascular niche' is comparatively less hypoxic and contains low levels of HIF-1a expression, owing to its close proximity to endothelial sinuses and oxygenated blood circulation. 112 It has been postulated that these endosteal and vascular niches have a key role in supporting the function of hemopoietic stem cells, with the hypoxic endosteal niche maintaining hemopoietic stem cells in an immature, quiescent state and the more oxygenated vascular niche promoting the maturation and proliferation of hemopoietic stem cells. 114 Given the presence of distinct hypoxic compartments in the BM, this raises the intriguing possibility that tumor cell behavior within the BM may be dependent on the particular niche in which they reside; this, however, awaits further investigation.
Hypoxia and MM
While numerous studies have examined the role of hypoxia in solid tumor progression, there is a paucity of published data regarding the role of hypoxia and the HIF transcription factors in hematological malignancies such as MM. Initial interest in this area stemmed from the well-established association between angiogenesis and MM disease progression, and the knowledge that hypoxia is a critical regulator of angiogenesis in other pathologies. Using the 5T2MM mouse model of MM, Asosingh et al. 115 showed that, while the BM of both normal and myelomatous animals is hypoxic, a heavily infiltrated MM BM is significantly less hypoxic owing to an increase in BM angiogenesis. They also showed that the native hypoxic BM environment selects for tumor-initiating CD45 þ MM PC populations which are resistant to apoptosis, suggesting that the hypoxic BM environment has a role in the establishment of MM following MM PC migration to the BM from secondary lymphoid organs. 115 This was the first study to show the important role played by the hypoxic BM microenvironment in MM disease progression, and was pivotal in highlighting the importance of examining the role of hypoxia in the etiology, pathogenesis and treatment of MM. Intriguingly, a more recent study using the 5T33MM murine model of MM found that the myelomatous BM environment is actually more hypoxic than the normal BM microenvironment. 113 These findings are perhaps more analogous to what has been observed in a solid tumor setting, in that low oxygen levels are often never fully restored by angiogenesis owing to the leakiness of the tumor vasculature and its inability to deliver an adequate blood supply to an ever-expanding tumor mass. 116 However, while further studies are required to clarify whether the MM BM microenvironment is more/less hypoxic than the normal BM compartment (and whether these discordant observations relate to the MM models or hypoxia detection methodologies used), it is important to note that both studies showed that the MM BM microenvironment is hypoxic and an important microenvironmental stimulus for MM disease etiology and pathogenesis.
In the human setting, a recent study by Colla et al.
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measured oxygen levels in human BM aspirates collected from healthy, monoclonal gammopathy of undetermined significance and MM patients, and detected average oxygen tensions of 54, 56 and 52 mm Hg, respectively. While the differences between these groups were not statistically significant, all three showed hypoxic BM oxygen levels and is in keeping with the findings of the murine studies. Extending these findings further, two recent studies have examined HIF-1a and HIF-2a protein expression in BM biopsy specimens taken from MM and monoclonal gammopathy of undetermined significance patients at clinical presentation. In studies emanating from our laboratory, 117 HIF-1a was found to be widely expressed by many cell types within the BM, whereas HIF-2a expression was restricted to CD68 þ macrophages and CD138 þ MM cells, suggesting that the induction of aberrant HIF-2a expression is associated with the malignant transformation of MM cells. In the second, much larger study, 118 strong HIF-1a and HIF-2a expression was observed in 33 and 13.2% of MM cases, respectively, and a significant association was observed between the expression of HIF-1a and HIF-2a in MM cells. As already mentioned, aberrant expression of either HIF-1a or HIF-2a has been documented in many solid tumors and when either or both are found to be overexpressed, it indicates a highly aggressive tumor with a much poorer prognosis. As yet, the association between aberrant HIF expression, and patient survival and prognosis has not been examined in MM.
Intriguingly, examination of temporal modulation of HIF-1a and HIF-2a expression in MM cell lines in response to hypoxia has showed that the HIF-1a protein is rapidly upregulated by hypoxia, whereas induction of HIF-2a is a relatively delayed response. 117 From this, it has been proposed that in MM cells, HIF-1 predominantly coordinates immediate, 'up-front' responses to hypoxia, whereas HIF-2 coordinates responses to more prolonged, chronic hypoxia, as has been reported previously in other cell types. 93, 119 As yet, the biological implications of the different expression patterns and induction kinetics of HIF-1a and HIF-2a in MM remain unknown; however, in solid tumors, aberrant HIF-2a expression is often associated with a worse prognosis than HIF-1a (reviewed by Lofstedt et al., 120 and Patel and Simon 121 ). To date, the most well-documented biological consequence of aberrant HIF expression in MM is angiogenesis. Studies have shown that there is a positive correlation between HIF-1a and HIF-2a expression, and the level of BM angiogenesis and expression of vascular endothelial growth factor (VEGF) and VEGF receptor in patient biopsy specimens. 118 Moreover, forced overexpression of either HIF-1 or HIF-2 in MM cells significantly enhances MM-induced angiogenesis in an in vivo xenograft model. 117 Gene expression profiling of CD138 þ MM PCs isolated from MM patients and cultured under normoxic or hypoxic conditions has also shown a significant upregulation in the expression of angiogenic genes such as interleukin-8 (IL-8) and VEGF by hypoxia. Conversely, small interfering RNAmediated knockdown of HIF-1a in MM cell lines significantly reduces MM-induced angiogenesis in vitro. 110 A number of anti-MM drugs, such as adaphostin, lenalidomide and bortezomib, have also been shown to mediate their antiangiogenic effects, at least in part, through inhibition of HIF-1. [122] [123] [124] [125] Moreover, preliminary studies suggest that HIF-1a is constitutively activated in endothelial cells isolated from MM patients but not monoclonal gammopathy of undetermined significance or healthy donors. 126 Given that hypoxia promotes numerous aspects of tumor progression in solid malignancies (for example, proliferation, survival, metabolism and migration), it is likely that future studies will find that other aspects of MM biology are strongly influenced by hypoxia. For example, although a direct connection between hypoxia and osteolytic bone disease in MM has yet to be established, recent studies suggest that an increase in the size and number of bone-resorbing osteoclasts could be attributable, in part, to hypoxia and HIF-1.
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As mentioned earlier, in addition to being induced by environmental hypoxia, aberrant HIF expression in MM cells can arise through genetic abnormalities such as loss of tumorsuppressor activity. While research in this area remains ongoing, Colla et al. 128 have shown that, compared with normal PCs, CD138
þ MM PCs have reduced expression of the tumor suppressor ING-4 (inhibitor of growth family member-4). Using ING-4 small interfering RNAs, they showed that ING-4 directly regulates HIF-1 expression in MM cells, which in turn stimulates the production of angiogenic cytokines and increases angiogenesis. Hatzimichael et al. 129 have also reported that the HIFselective prolyl hydroxylase, EGLN3, undergoes epigenetic CpG methylation in 33% of MM patients, which was the first evidence of epigenetic modulation of an HIF-specific PHD in human cancer. While loss of other tumor suppressors such as VHL, p53 and phosphatase and tensin homolog has also been shown to induce HIF expression in other tumor cell types, [49] [50] [51] this has yet to be confirmed in MM.
The helix-loop-helix transcription factor, c-Myc, is a protooncogene, which is de-regulated in 30-50% of patients with advanced MM. 130 Of note, recent studies have documented an important relationship between HIF-1 and c-Myc in MM PCs, which results in the upregulation of HIF-1a independent of hypoxia. 124 Under normoxic conditions, deregulated c-Myc promotes constitutive HIF-1 protein activation, promotes aberrant VEGF production by MM PCs and angiogenesis, and is associated with a poor prognosis in MM patients. This study also showed that drugs such as bortezomib, doxorubicin, adaphostin and lenalidomide interfere with the c-Myc/HIF-1a axis in MM PC lines, which provides further insight into the mechanism of action of many of these agents, which are currently used clinically to treat MM.
Therapeutic targeting of hypoxia and the HIFs in MM
The increasing importance of HIF-1a and HIF-2a in tumorigenesis (and indeed, numerous other disease states) raises the possibility that agents which specifically inhibit these transcription factors, would provide significant therapeutic benefit. Importantly, based on the complex interplay between HIF-1 and HIF-2 in tumorigenesis, it is likely that combined inhibition of HIF-a isoforms will be appropriate in certain disease settings, whereas HIF-1a-or HIF-2a-specific therapies may be better suited in others. While transcription factors have traditionally been considered to be poor drug targets owing to difficulties associated with small-molecule inhibition of protein-protein or protein-DNA interactions, 131 a number of strategies for direct targeting of hypoxic tumor cells have been developed. These strategies include small-molecule therapeutics and antisense inhibitors, which interfere with HIF-1 synthesis, stability or transactivation, hypoxia-responsive viral vectors and hypoxiaactivated pro-drugs. Furthermore, a growing number of conventional and novel anticancer agents has been shown to indirectly inhibit HIF activity (summarized in Table 1 ).
The specific HIF-1 inhibitor, PX-478, has shown to be effective against a range of tumors in SCID mice 132 and is currently undergoing early-phase clinical trial in treating advanced solid tumors or lymphoma. PX-478 inhibits HIF-1 protein translation and HIF-1 de-ubiquitination, which leads to increased HIF-1 poly-ubiquitination and degradation. Also undergoing phase-I clinical trials is EZN-2968, which is an antisense RNA inhibitor that binds specifically to and inhibits the expression of HIF-1a mRNA, and reduces HIF-1a mRNA and protein levels, leading to decreased expression of HIF-regulated genes in vitro and in vivo. Hypoxia-activated pro-drugs combine a potent DNA-alkylating agent with a hypoxia-activated molecular trigger. These agents are designed to deliver cytotoxic agents to hypoxic tumor zones and minimize drug-related toxicities in normoxic tissues. 134 In several preclinical tumor models, TH-302 has shown potent hypoxia-dependent cytotoxicity, and early doseescalation studies show it to be well-tolerated in humans. 135 Of note, recent studies show that TH-302 induces G 0 /G 1 cell-cycle arrest and triggers apoptosis in MM cell lines in vitro and in the 5T33MM in vivo model of MM. 113 It remains to be seen whether HIF-targeting drugs will have serious side effects. As erythropoietin is an important HIFinducible gene, it is possible that prolonged HIF inhibition would lead to oxygen deprivation in normal tissues. BM cells also could be potentially vulnerable to hypoxia inhibition, given their residence in a naturally hypoxic environment close to the endosteal surface of bone. Nevertheless, the emerging role of hypoxia and the HIF transcription factors in MM disease progression suggests that the development of drugs which specifically target hypoxic zones, could provide significant therapeutic benefit for MM patients.
Concluding remarks
Despite recent treatment advances resulting from the introduction of agents such as thalidomide, lenalidomide and bortezomib, MM remains incurable. Furthermore, owing to the complexity of interactions between tumor cells and their microenvironment, and the involvement of an array of chemokines, cytokines, growth factors and enzymes, elucidation of the mechanisms responsible for MM disease progression remains incomplete. Hypoxia is a common feature in cancer, which affects many important biological properties of tumor cells. The intention of this review was to highlight the emerging role of hypoxia and the HIF transcription factors in MM biology. By relating an extensive body of literature regarding the role of hypoxia in the solid tumor setting to what is currently known about the kinetics of MM disease progression, we have formed a hypothetical model of the role of hypoxia in MM disease progression (Figure 2 ). In the initial stages of disease establishment, we postulate that the hypoxic BM microenvironment [108] [109] [110] 112 supports the initial survival and growth of the MM cells. 136 As the MM PCs establish themselves within the endosteal niche of the BM, they become exposed to even greater levels of hypoxia, 137 which activates HIF-1 and/or HIF-2, and stimulates the production of angiogenic factors and angiogenesis to increase oxygen delivery to the tumor cells, thereby facilitating tumor growth. In support of this, elevated HIF expression has been observed in the early stages of tumor development prior to histological evidence of angiogenesis and invasion, and this is thought to contribute to the angiogenic switch. 64 As MM PCs evolve, they acquire a range of chromosomal mutations which can upregulate the expression of the HIF transcription factors independently of hypoxia (for example, aberrant c-Myc and suppressed ING-4, VHL, p53 and phosphatase and tensin homolog activity [49] [50] [51] 124, 128 ). Together, these chromosomal abnormalities and hypoxiainduced angiogenesis will accelerate disease progression into the active, progressive phase of MM leading to symptomatic disease. When this occurs, patients will show increased levels of HIF-1a and/or HIF-2a expression, 117, 118 BM angiogenesis, 110, 117, 118 and osteolytic bone disease. While HIF-1a expression may begin to decrease following the activation of the angiogenic switch, owing to an increase in BM angiogenesis and tumor oxygenation, 115 we anticipate that HIF-2a expression will remain elevated until the 'end stage' based on the fact that HIF-2 is not as efficiently degraded in response to increasing oxygen tensions. 25, 93 This chronic activation of HIF-2 will 
Immunomodulatory agents Lenalidomide 125
Microtubule inhibitors 2-Methoxyestradiol, taxotere, vincristine [156] [157] [158] Chemotherapeutic agents Doxorubicin, daunorubicin, topotecan 159, 160 Abbreviations: HDAC, histone deacetylase; HIF, hypoxia-inducible transcription factor; NSAID, non-steroidal anti-inflammatory drug.
continue to drive the expression of pro-angiogenic, osteoclastogenic and cell survival genes to further promote disease progression.
In conclusion, a number of recent studies have provided valuable insight into the functional role of hypoxia in MM disease progression, and have shown that hypoxia, HIF-1 and HIF-2 represent potential therapeutic targets in MM. With a greater understanding of the hypoxic microenvironment in which myeloma PCs reside, it is likely that more efficient ways to target hypoxic zones and inhibit hypoxia-driven disease processes will be identified, ultimately providing the muchneeded therapeutic advances for MM patients. Angiogenic switch Figure 2 The proposed role of hypoxia in the pathogenesis of MM. In response to chromosomal mutations and chronic exposure to hypoxia, the induction of HIF-1a and HIF-2a expression selects for a subpopulation of 'angiogenic MM PCs' ( ) capable of triggering the angiogenic switch. In addition to genes associated with angiogenesis, the HIFs activate genes associated with osteoclast recruitment and activation, and cell-cycle regulation, which further drive the transition from indolent MM to active MM. HIF, hypoxia-inducible transcription factor; MM, multiple myeloma; PC, plasma cell.
